Evidence map›Paper›PMID 42063563›Full record

ArticleiScience2026

cJun-assisted loading of RelA DNA-binding promotes synergistic lung epithelial antimicrobial responses.

Jezreel Pantaleón García, Keerthi Bhoda, Madeleine Burch-Eapen, Raquel Alonso Becerra, Paris Rodríguez Carstens, Daniela Covarrubias López, Jania Foncerrada Lizaola, Vikram V Kulkarni, Jose Martinez, Yongxing Wang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jezreel Pantaleón GarcíaDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Keerthi BhodaDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Madeleine Burch-EapenDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Raquel Alonso BecerraDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Paris Rodríguez CarstensDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Daniela Covarrubias LópezDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jania Foncerrada LizaolaDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Vikram V KulkarniDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jose MartinezMD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA.
Yongxing WangDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Scott E EvansDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
Inducible epithelial resistance: a program investigating mechanisms to protect against acute and chronic complications of pneumoniaR35HL144805 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI EVANS, SCOTT E. · 2019 to 2025
$6.2M
Inducible epithelial antiviral resistance to prevent asthmaDP2HL123229 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI EVANS, SCOTT E. · 2013 to 2013
$2.4M
Epithelial mechanisms of inducible resistance to AML-associated pneumoniaR01HL117976 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI EVANS, SCOTT E. · 2014 to 2018
$2.0M
NCI NIH HHS P30 CA016672NHLBI NIH HHS DP2 HL123229NHLBI NIH HHS R01 HL117976NHLBI NIH HHS R35 HL144805
6 · The paper itself

Abstract

Lower respiratory tract infections remain a leading cause of death worldwide, highlighting the need for host-directed therapies. We previously identified an inhaled immunostimulatory combination of Pam2CSK4 (Pam2) and CpG oligodeoxynucleotide ODN M362 (ODN) that synergistically protects against bacterial, viral, and fungal pneumonias by reprogramming lung epithelial defenses. Using RNA-seq, dual transcription factor ChIP-seq, and reverse phase protein array, we define the transcriptional basis of this synergy. Cooperative regulation by the AP-1 component cJun and the NF-κB subunit RelA is central to the Pam2+ODN response. cJun occupancy distinguishes synergistic genes, whereas RelA occupancy aligns with expression directionality. Promoter-proximal cJun occupancy facilitates enhanced RelA loading, enabling rapid transcriptional reprogramming that strengthens epithelial survival pathways and amplifies microbicidal effector programs. This AP-1-assisted NF-κB cooperation establishes inducible resistance in lung epithelium and provides a mechanistic foundation for host-directed therapies against respiratory infection.

Indexed as

microbiologyrespiratory medicine

Identifiers

PMID42063563
PMCPMC13127319

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.